Coronary drug-eluting stent development: Issues in trial design

American Heart Journal

Volumn 149, Issue 3, 2005, Pages 415-433

  Muni, Neal I ^a,c   Califf, Robert M ^b   Foy, Jonette R ^a   Boam, Ashley B ^a   Zuckerman, Bram D ^a   Kuntz, Richard E ^c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 578; ALUMINUM OXIDE; BATIMASTAT; BIOLIMUS; DACTINOMYCIN; DEXAMETHASONE; DRUG CARRIER; ESTRADIOL; EVEROLIMUS; PACLITAXEL; PACLITAXEL DERIVATIVE; PHOSPHORYLCHOLINE; RAPAMYCIN; RAPAMYCIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTERY INTIMA PROLIFERATION; BLOOD VESSEL INJURY; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG ELUTING STENT; DRUG FORMULATION; DRUG MARKETING; DRUG RELEASE; HEALING; HUMAN; HYDROPHOBICITY; LIPOPHILICITY; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; RISK ASSESSMENT; THROMBOSIS; TREATMENT OUTCOME;

EID: 17844388590     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.09.001     Document Type: Conference Paper

References (23)

1. TAXUS Express 2 Paclitaxel-Eluting Coronary Stent System (Monorail and Over-the-Wire)-P030025, March 4, 2004 http://www.fda.gov/cdrh/pdf3/p030025.html
2. CYPHER Sirolimus-Eluting Coronary Stent on RAPTOR Over-the-Wire Delivery System or RAPTORRAIL Rapid Exchange Delivery System-P020026, April 24, 2003 http://www.fda.gov/cdrh/pdf2/p020026.html
3. A. Farb, G. Sangiorgi, A.J. Carter Pathology of acute and chronic coronary stenting in humans Circulation 99 1999 44 52
4. A. Farb, D.K. Weber, F.D. Kolodgie Morphological predictors of restenosis after coronary stenting in humans [Comment] Circulation 105 2002 2932 2933
5. A.P. Burke, F.D. Kolodgie, A. Farb Morphological predictors of arterial remodeling in coronary atherosclerosis Circulation 105 2002 297 303
6. R. Virmani, A. Farb, F.D. Kolodgie Histopathologic alterations after endovascular radistion and antiproliferative stents: similarities and differences Herz 27 2002 1 6
7. R. Virmani, F. Liistro, G. Stankovic Mechanism of late in-stent restenosis after implantation of a paclitaxel derivative-eluting polymer stent system in humans Circulation 106 2002 2649 2651
8. F.D. Kolodgie, M. John, C. Khurana Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel Circulation 106 2002 1195 1198
9. A. Farb, P.F. Heller, S. Shroff Pathological analysis of local delivery of paclitaxel via a polymer-coated stent Circulation 104 2001 473 479
10. R.S. Schwartz, E.R. Edelman Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group Circulation 106 2002 1867 1873
11. C.W. Hwang, D. Wu, E.R. Edelman Physiological transport forces govern drug distribution for stent-based delivery Circulation 104 2001 600 605
12. D.P. Faxon Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial with Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group J. Am. Coll. Cardiol. 25 1995 362 369
13. P.P. Leimgruber, G.S. Roubin, J. Hollman Restenosis after successful coronary angioplasty in patients with single-vessel disease Circulation 73 1986 710 717
14. R.E. Kuntz, R.D. Safian, J.P. Carrozza The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting Circulation 86 1992 1827 1835
15. R.E. Kuntz, D.S. Baim Defining coronary restenosis. Newer clinical and angiographic paradigms Circulation 88 1993 1310 1323
16. L. Mauri, A.J. O'Malley, D.E. Cutlip Independent effects of stent length and lesion length on coronary restenosis Circulation 2002 [abstract]
17. E.M. Antman Clinical trials in cardiovascular medicine Circulation 103 2002 e101 e104
18. D.S. Baim, M.B. Leon, J.J. Popma Problems in the evaluation of new devices for coronary intervention: what have we learned since 1989? Am. J. Cardiol. 80 1997 3K 9K
19. D.L. DeMets, R.M. Califf Lessons learned from recent cardiovascular clinical trials: Part I Circulation 106 2002 746 751
20. R. Mehran, G. Dangas, A.S. Abizaid Angiographic patterns of in-stent restenosis Circulation 100 1999 1872 1878
21. E.J. Topol, S.E. Nissen Our preoccupation with coronary luminology: the dissociation between clinical and angiographic findings in ischemic heart disease Circulation 92 1995 2333 2342
22. P.W. Serruys, M. Degertekin, K. Tanabe Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (Randomized Study with the Sirolimus-Eluting Velocity Balloon-Expandable Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions) trial Circulation 106 2002 798 803
23. D.W. Feigal, S.N. Gardner, M. McClellan Ensuring safe and effective medical devices N. Engl. J. Med. 348 2003 191 192